Clinical Trial Update: An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice [Phase 4]

View source ↗

Summary

An open-label Phase 4 study of Ozanimod in moderate-to-severe ulcerative colitis was terminated, with results posted in February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Zeposia (ozanimod hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colitis, Ulcerative | Phase 4 | Status: TERMINATED | Results posted: 2026-02-10